Pharming also markets and sells the HAE approved ... Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified ...

Senate Democratic leader Chuck Schumer stated his party would block a Republican spending bill to ... Ulta Beauty (ULTA), Futu (FUTU), Rubrik (RBRK), ServiceTitan (TTAN), Pharming Group (PHAR), ...

Senate Democratic leader Chuck Schumer stated his party would block a Republican ... Futu (FUTU), Rubrik (RBRK), ServiceTitan (TTAN), Pharming Group (PHAR), Semtech (SMTC), Weibo Corp (WB ...

Across the recent three months, 4 analysts have shared their insights on Pharming PHAR, expressing a variety of opinions spanning from bullish to bearish. The table below summarizes their recent ...

Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong ...

Leiden, the Netherlands, February 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following ...

Abliva Acquisition Cost: $66.1 million, funded with available cash. Pharming Group (PHGUF) reported a 21% increase in full-year 2024 revenues, reaching $297 million, surpassing their guidance range.

Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of ...

adding KL1333 for mitochondrial DNA-driven primary mitochondrial diseases to Pharming’s late-stage clinical pipeline, in line with our vision to become a leading global rare disease company ...